Aarti Drugs Q1 results show revenue fell from 743.28 crores to 661.71 crores, a -10.97% decrease in growth. EPS down from ₹6.07 to ₹5.18, down by -14.66%.
First, Let’s Begin with Quarter-on-Quarter Basis:
Aarti Drugs shared its Q1 results on Tuesday. They earned 661.71 crores in revenue this quarter, but that’s less than the 743.28 crores they made last quarter. Unfortunately, the company’s growth decreased by -10.97 percent when comparing the two quarters.
In terms of profits, the company’s PAT (Profit After Tax) for this quarter was 47.85 crores, down from 56.09 crores in the previous quarter. Their quarter-to-quarter growth decreased by -14.69 percent.
The company’s EPS (Earnings Per Share) this quarter is ₹5.18, which is a decrease of -14.66% from the ₹6.07 EPS in the previous quarter.
Now, Let’s Analyze the Results on a Year-over-Year Basis:
The company made a total revenue of 661.71 crores this year (2023), which is 6.35 percent higher than last year’s total revenue of 622.22 crores.
This year’s PAT (Profit After Tax) is 47.85 crores, which is also 37.54% higher than last year’s PAT of 34.79 crores.
The EPS (Earnings Per Share) for this year is ₹5.18, which is 37.77% more than the EPS of ₹3.76 earned last year.
Also Read: DLF Q1FY24 Results: Consolidated PAT of Rs. 527 Cr
Aarti Drugs Share Dividend Announcement / Record Date:
The record date for the dividend has not arrived yet.
About Aarti Drugs :
Founded in 1984, Aarti Drugs Ltd. is an integral member of the $900 Million Aarti Group of Industries. The company boasts a strong Research and Development (R&D) Division located in Tarapur, Maharashtra Industrial Development Corporation (MIDC), in close proximity to its manufacturing facilities.
Download the Full PDF of Aarti Drugs Q1 Results: Click Here
For more of the Latest News, Click Here
